Compare Marsh & McLennan Companies, Inc. (MRSH) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Marsh & McLennan Companies, Inc. trades at $179.94 (market cap $84.47B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 17.3× Travere Therapeutics Inc. Common Stock's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MRSH | TVTX | |
|---|---|---|
Market Cap | $84.47B | $4.88B |
Volume | 3,662,234 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $203.85 | $67.52 |
52-Week Low | $157.32 | $26.79 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $105.15B | $5.01B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $178.40, up 1.05% today, with a bullish technical signal and recent earnings beats. The stock shows strong fundamentals with a P/E of 21.61, net income margin of 14.24%, and consistent revenue growth to $27.0B in 2025. Recent acquisition of Accel Holdings (Business Wire, 2026-10-02) enhances its advisory services, while analyst consensus is a 'Hold' with a $202.71 price target. Cash flow remains positive at $486M in 2025, supporting dividend payments.
Outlook is cautiously optimistic; the stock offers growth potential from strategic acquisitions and solid profitability, but risks include high P/B of 5.56 and competitive pressures. Investors should weigh the 13.6% upside to the consensus target against overbought RSI levels and margin compression risks in 2026 forecasts.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
